Fresenius Medical Care (NYSE:FMS) Reaches New 12-Month High – What’s Next?

Fresenius Medical Care AG (NYSE:FMS)’s share price reached a new 52-week high during trading on Thursday . The stock traded as high as $30.46 and last traded at $29.78, with a volume of 648023 shares changing hands. The stock had previously closed at $29.85.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Truist Financial boosted their price target on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a report on Monday, May 12th. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care in a research note on Thursday, May 15th. Finally, Wall Street Zen started coverage on shares of Fresenius Medical Care in a research note on Tuesday. They issued a “strong-buy” rating for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Fresenius Medical Care presently has an average rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care Stock Performance

The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm’s 50 day moving average is $25.53 and its 200-day moving average is $24.00. The firm has a market cap of $17.00 billion, a price-to-earnings ratio of 23.94, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The business had revenue of $5.54 billion during the quarter, compared to analyst estimates of $4.71 billion. Sell-side analysts anticipate that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be paid a $0.7871 dividend. This represents a dividend yield of 1.9%. The ex-dividend date is Friday, May 23rd. This is a positive change from Fresenius Medical Care’s previous annual dividend of $0.44. Fresenius Medical Care’s payout ratio is presently 49.11%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of FMS. Millennium Management LLC lifted its position in Fresenius Medical Care by 5,297.5% during the 4th quarter. Millennium Management LLC now owns 722,238 shares of the company’s stock worth $16,351,000 after acquiring an additional 708,857 shares during the last quarter. Todd Asset Management LLC acquired a new position in Fresenius Medical Care during the 1st quarter worth $12,009,000. Teachers Retirement System of The State of Kentucky acquired a new position in Fresenius Medical Care during the 1st quarter worth $7,420,000. Raymond James Financial Inc. lifted its position in Fresenius Medical Care by 1,508.1% during the 1st quarter. Raymond James Financial Inc. now owns 287,751 shares of the company’s stock worth $7,165,000 after acquiring an additional 269,857 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in Fresenius Medical Care by 3,237.7% during the 1st quarter. GAMMA Investing LLC now owns 239,115 shares of the company’s stock worth $5,954,000 after acquiring an additional 231,951 shares during the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.